Incorporating nutritional outcomes into ongoing GLP-1 therapy trials would provide valuable evidence on whether these biochemical changes translate into measurable health effects such as anaemia, neuropathy, or bone demineralisation. The gene discussed is GLP1R; the disease is neuropathy.